Deregulated nutrient sensing

IGF-1 levels: normal range by age and the real link with longevity

Normal IGF-1 levels fall with every decade of adult life. Here are the reference ranges by age and sex, what large human studies show about mortality, and which dietary levers actually move the result.

11 November 2026 15 min read
igf-1 : illustration de l'article IGF-1 : taux normal selon l'âge et lien réel avec la longévité

IGF-1 levels, set mainly by the liver in response to growth hormone, peak around age 15 and then decline throughout adult life. Doctors use this blood level to detect an excess or a deficiency of growth hormone. It also interests longevity research, because mice with a reduced IGF-1 signal live longer. In humans, the picture is more nuanced: a level that is too low and a level that is too high are both associated with higher mortality. Normal values, for their part, change with every decade.

In brief – IGF-1 is a growth factor in the blood that relays the action of growth hormone, and normal IGF-1 levels depend heavily on age. In the French VARIETE cohort (899 healthy adults, iSYS assay), the normal range for men goes from 168-391 ng/mL around age 20 to 64-192 ng/mL after 70. Figures change from one laboratory kit to another, so a result should be read against the reference ranges of the laboratory that ran it. For longevity, human studies describe a U-shaped curve. In a meta-analysis of 14,906 people, mortality is 27% higher when the level is low and 18% higher when it is high. High IGF-1 goes hand in hand with more breast and colon cancers, a low level with more heart disease and dementia. Staying in the middle range, without growth hormone, remains the most prudent reading.

What is IGF-1?

IGF-1 (insulin-like growth factor 1, also called somatomedin C) is a small peptide of 70 amino acids, structurally close to insulin. The liver makes most of it when the pituitary gland releases growth hormone (GH). Muscles, bones and the brain also produce it locally, for their own needs.

In the blood, this factor circulates almost entirely bound to carrier proteins, mainly IGFBP-3. This binding keeps it stable throughout the day, whereas GH is secreted in pulses, mostly at night. Doctors therefore measure IGF-1 to assess growth hormone activity: a single blood sample is enough, with no dynamic test.

IGF-1 levels follow a well-known curve over the lifespan. A multicenter study of 15,014 people aged 0 to 94 describes this trajectory (Bidlingmaier et al., 2014). The level drops just after birth, rises to the pubertal peak around age 15, then falls without interruption. Women have slightly lower values than men on average, but the gap between the sexes remains small.

In practice, the IGF-1 test is mainly used to screen for acromegaly or GH deficiency, in children as well as adults. Acromegaly reflects an excess of growth hormone, most often caused by a benign tumor of the pituitary gland. The test is also used to adjust the treatment of these conditions. No guideline recommends it as a longevity marker in a healthy person.

How the GH/IGF-1 axis works and why IGF-1 levels fall with age

The somatotropic axis works as a cascade: the hypothalamus releases GHRH, the pituitary responds with pulses of GH, and the liver converts this signal into circulating IGF-1. IGF-1 then slows GH secretion, which keeps the system stable. In tissues, it binds to its receptor, IGF-1R, and activates the PI3K/AKT/mTOR pathway, the one that drives growth and anabolism.

This signal acts on several organs at once:

  • It stimulates muscle protein synthesis and helps maintain bone mass.
  • It promotes cell division and slows programmed cell death, which helps repair tissues but can also help an abnormal cell survive.
  • It has a glucose-lowering effect close to that of insulin, by helping glucose enter the muscles.
  • It supports the survival of neurons: in the Framingham cohort, higher IGF-1 is associated with a larger brain volume.
  • It inhibits FOXO factors, regulators of the stress response that are linked to longevity in animals.

The age-related decline, sometimes called somatopause, first follows the loss of deep sleep. In 149 men aged 16 to 83, slow-wave deep sleep fell from 18.9% of the night at ages 16-25 to 3.4% at ages 36-50. GH secretion dropped in parallel by 372 micrograms per decade, then more slowly after 50 (Van Cauter et al., 2000). Less GH at night means less somatomedin made by the liver.

Other factors lower the level at any age: undernutrition, low protein intake, liver disease, hypothyroidism or poorly controlled diabetes. Conversely, puberty, pregnancy and above all acromegaly raise it. A single result therefore reflects nutritional status and liver health as much as age.

IGF-1 levels and longevity: what human studies show

In humans, no study shows that lowering your IGF-1 extends life: large cohorts describe a U-shaped curve, with more deaths at both ends. This finding contrasts with results in animals, the source of most “anti-aging” claims about this growth factor.

In mice, reducing the signal does extend lifespan. Mice with only one functional copy of the gene for the IGF-1R receptor live 26% longer on average, and females 33% longer (Holzenberger et al., 2003). The same French team then reduced these receptors in the brain alone (Kappeler et al., 2008). As the full paper in PLOS Biology reports, their mortality up to 100 weeks, the equivalent of 70 years in humans, was six times lower.

In adults, the strongest evidence comes from a meta-analysis of 12 studies totaling 14,906 people. Compared with median values, low IGF-1 is associated with 27% higher all-cause mortality (HR 1.27). A high level is associated with 18% higher mortality (HR 1.18). Between the 10th and the 50th percentile, the predicted risk climbs by 56% (Burgers et al., 2011). The U shape holds for cancer mortality as well as for cardiovascular mortality.

Age changes this relationship. In the UK Biobank, 440,185 adults aged 37 to 73 were followed after a baseline measurement, with a mean level of 163.6 ng/mL. In the youngest, each additional standard deviation of IGF-1 comes with 17% lower mortality (HR 0.83). In the oldest, the protection disappears (HR 0.97) and a high level is even associated with more disease (Zhang et al., 2021). The authors speak of antagonistic pleiotropy: useful in youth, costly later on.

Data on the very old point the same way. Among 184 nonagenarians, women whose IGF-1 did not exceed 96 ng/mL lived longer than the others. No difference appeared in men (Milman et al., 2014). In Ashkenazi Jewish centenarians, mutations that weaken the IGF-1R receptor were overrepresented in women (Suh et al., 2008). These women had a higher blood level, a sign of a less sensitive receptor.

Laron syndrome offers an extreme case. In Ecuador, 99 people carrying a mutation in the GH receptor, and therefore almost without IGF-1, were followed for 22 years. Only one cancer, which was not fatal, and no diabetes were observed, compared with 17% cancer and 5% diabetes among their relatives (Guevara-Aguirre et al., 2011). Their lifespan was nonetheless not extended: 70% of deaths came from causes unrelated to aging, such as accidents, alcohol or seizures.

High or low IGF-1 levels: the measured risks

High IGF-1 is associated mainly with certain hormone-dependent cancers, and a low level mainly with cardiovascular and neurodegenerative diseases. In the UK Biobank, 394,388 people without cancer were followed for 6.9 years on average. Each increase of 5 nmol/L (about 38 ng/mL) is associated with 11% more breast cancers. It is also associated with 8% more colorectal or prostate cancers (Knuppel et al., 2020). The risk of ovarian and liver cancers, by contrast, was lower.

An association does not prove causation. To get closer to it, researchers use Mendelian randomization, which compares people genetically programmed for a higher or a lower level. For breast cancer, this approach finds a modest but probably causal effect, with a 5% higher risk per 5 nmol/L (Murphy et al., 2020). For colorectal cancer, the genetic link also holds, but it remains inconclusive for prostate cancer (Larsson et al., 2020).

At the other end of the curve, a low level comes with other risks. In the Danish DAN-MONICA cohort, the lowest quartile had almost twice the risk of ischemic heart disease over 15 years (Juul et al., 2002). In the Framingham cohort (3,582 people followed for 7.4 years), the lowest quartile is associated with 51% more Alzheimer’s disease (Westwood et al., 2014).

High or low IGF-1 levels: associated risks in large studies
IGF-1 level Associated risk Measured magnitude Source
High Breast cancer HR 1.11 per 5 nmol/L, genetic effect OR 1.05 Murphy 2020, 206,263 women
High Colorectal cancer HR 1.08 per 5 nmol/L Knuppel 2020, 394,388 people
High Prostate cancer HR 1.08 per 5 nmol/L, inconclusive genetic evidence Larsson 2020
Low Ischemic heart disease RR 1.94, lowest quartile vs highest quartile Juul 2002, 231 cases
Low Alzheimer’s disease HR 1.51 for the lowest quartile Westwood 2014, 3,582 people
Low or high All-cause mortality HR 1.27 if low, HR 1.18 if high Burgers 2011, 14,906 people

Normal IGF-1 levels by age and how to read your result

Normal IGF-1 levels are read by age group and sex, using the reference ranges specific to the laboratory’s assay. The most complete French reference values come from the VARIETE cohort (Chanson et al., 2016). Its 911 adults aged 18 to 90, randomly drawn from the general population, were tested with six different kits. The table below gives the ranges obtained with the automated iSYS assay in 899 healthy participants.

Normal IGF-1 levels by age and sex (iSYS assay, French VARIETE cohort)
Age Men (ng/mL) Women (ng/mL)
18 to 20 years 168-391 155-421
21 to 23 years 147-346 144-383
24 to 26 years 132-313 134-353
27 to 29 years 122-292 126-330
30 to 39 years 108-265 113-294
40 to 49 years 91-233 97-253
50 to 59 years 81-214 80-209
60 to 69 years 75-208 64-170
70 to 89 years 64-192 56-154

These ranges cover 95% of healthy people, from the 2.5th to the 97.5th percentile. By design, one perfectly healthy person in 40 falls below the lower limit, and another one above the upper limit. A result slightly outside the range is therefore not a diagnosis on its own. Many laboratories also express the result as a standard deviation score (SDS): between -2 and +2, it stays within the normal range for age.

The assay kit matters as much as age. In the same population, the lower limits of the six methods were close, but the upper limits varied markedly. Agreement between methods ranged from moderate to good, with a kappa coefficient of 0.38 to 0.70.

Same population, six kits: normal IGF-1 range in men aged 50 to 59
Assay kit Normal range (ng/mL)
iSYS (IDS) 81-214
LIAISON XL (DiaSorin) 97-252
IMMULITE 2000 (Siemens) 85-273
IGFI-RIACT (Cisbio) 94-262
Mediagnost ELISA 88-245
Mediagnost RIA 86-218

In concrete terms, a 55-year-old man at 240 ng/mL is above the range with the iSYS kit but within the range with the IMMULITE kit. To track your level over time, it is best to stay with the same laboratory. If the result is given in nmol/L, as in British studies, simply multiply it by 7.65 to get ng/mL.

IGF-1 levels: blood collection tubes ready for testing in a medical laboratory
IGF-1 levels are measured on an ordinary blood sample, and the result depends on the kit the laboratory uses.

This level is tied to one of the major biological pathways of aging, deregulated nutrient sensing, alongside insulin and mTOR. A doctor orders the test when there are signs of acromegaly (hands and feet that grow larger, facial features that thicken) or of growth hormone deficiency. Outside these situations, a stand-alone “longevity” test tells you little, because IGF-1 also varies with your diet over the previous weeks. Calorie restriction, often cited as a way to lower it, illustrates this gap between mice and humans well.

How to keep IGF-1 levels in the middle range: the documented levers

No measure has been shown to extend life by changing IGF-1: the levers below shift the level by measured amounts and remain consistent with standard prevention. The reasonable goal is to stay in the middle range for your age, without aiming for the lowest possible level.

  • Match your protein intake to your age. The European Food Safety Authority (EFSA) sets the adult reference intake at 0.83 g per kilogram of body weight per day (about 0.38 g per pound). In six volunteers, going from 1.67 to 0.95 g/kg/day for three weeks lowered IGF-1 from 194 to 152 ng/mL (Fontana et al., 2008).
  • Do not restrict protein after 65. Needs increase with age to preserve muscle, as our guide to daily protein intake for longevity explains in detail.
  • Do not count on calorie restriction alone. In the same study, severe restriction maintained for 1 to 6 years without malnutrition did not lower the blood level, unlike what happens in rodents.
  • Keep milk to a moderate place. In the UK Biobank, protein from milk and yogurt is associated with a higher level, but protein from cheese is not (Watling et al., 2021).
  • Protect your deep sleep. Nighttime GH secretion depends directly on it, and it is a lever with no side effects.
  • Turn down “anti-aging” growth hormone. In 220 healthy older adults, it adds 2.1 kg (4.6 lb) of lean mass. It also increases edema, joint pain and carpal tunnel syndrome (Liu et al., 2007).

The liveliest debate concerns protein. In the US NHANES III survey, 6,381 adults aged 50 and over were followed for 18 years. Between 50 and 65, getting at least 20% of calories from protein is associated with 74% higher mortality. The risk of dying from cancer is multiplied by four (Levine et al., 2014). After 65, the relationship reverses: the same high intake is associated with 28% lower mortality. The confidence intervals are wide (1.02 to 2.97), and one of the authors holds shares in a nutrition products company.

Periodic fasting also acts on this level. In a trial of 100 adults, three monthly cycles of five days on a fasting-mimicking diet lowered IGF-1 (Wei et al., 2017). Weight and blood pressure also went down. The effect concerns markers, not survival, and the program tested is sold by a company linked to the research team.

What changes IGF-1 levels: effects measured in humans
Factor Effect on IGF-1 Population studied Source
Protein cut from 1.67 to 0.95 g/kg/day 194 to 152 ng/mL in 3 weeks 6 volunteers Fontana 2008
Severe calorie restriction, 1 to 6 years No decrease People practicing calorie restriction Fontana 2008
Milk protein, +2.5% of calories +1.20 nmol/L (about 9 ng/mL) 11,815 British adults Watling 2021
Oily fish twice a week or more +1.25 nmol/L compared with never 438,453 British adults Watling 2023
Fasting-mimicking diet, 3 cycles of 5 days Significant decrease 100 randomized adults Wei 2017
Alcohol, more than 40 g per day -1.36 nmol/L, with no health benefit 11,815 British adults Watling 2021

These shifts in IGF-1 levels remain small compared with the normal range: a few nmol/L, when the range for someone in their fifties spans about 130 ng/mL. The useful step is therefore not to push your IGF-1 as low as possible. It means avoiding excess protein before 65, feeding your muscles well afterward, and never taking growth hormone without a medical indication.

Frequently asked questions about IGF-1 levels

What are normal IGF-1 levels by age?

They depend on age, sex and the laboratory’s kit. With the iSYS assay, the French VARIETE cohort gives men 108-265 ng/mL at 30-39, 81-214 ng/mL at 50-59 and 64-192 ng/mL after 70. For women, the corresponding values are 113-294, 80-209 and 56-154 ng/mL. Only your own laboratory’s reference ranges are authoritative.

Is a low IGF-1 level good for longevity?

Not necessarily. In animals, a reduced signal extends life, but in humans the relationship follows a U-shaped curve. In a meta-analysis of 14,906 people, a low level is associated with 27% higher mortality, particularly cardiovascular mortality. A low level can also signal undernutrition, liver disease or a hormone deficiency. The middle range for your age remains the most prudent target.

Why is my IGF-1 level high?

A result just above the range is common: by design, one healthy person in 40 exceeds the upper limit. Kits also have different upper limits. A high intake of dairy protein can also raise the level slightly. A clearly high value, especially with hands or feet that are growing larger, calls for testing for acromegaly with a doctor.

Do milk and protein raise IGF-1 levels?

Yes, modestly. In the UK Biobank, 2.5% more calories from milk protein is associated with 1.20 nmol/L more, or about 9 ng/mL. Cheese does not have this effect. In six volunteers, cutting protein from 1.67 to 0.95 g/kg/day lowered the level from 194 to 152 ng/mL. After 65, however, you should not reduce your protein intake.

Should you test your IGF-1 to monitor your aging?

No guideline recommends it for a healthy person. The test is used to screen for acromegaly or growth hormone deficiency. A single result depends on recent diet, liver health and the kit used. It cannot predict your own longevity, and no “optimal” threshold has been validated in humans.

What is the difference between IGF-1 and growth hormone?

Growth hormone (GH) is produced by the pituitary gland in pulses, mostly during deep sleep. IGF-1 is the relay it has the liver make, and it stays stable throughout the day. GH acts partly through it, which is why doctors measure this relay to assess GH. Taken without a medical indication, GH increases edema and joint pain in older adults.

Medical disclaimer. This article is provided for informational purposes only and does not constitute medical advice. It does not replace a consultation. Ask a healthcare professional before changing your diet, taking dietary supplements or starting a new practice, especially if you have a medical condition, are pregnant or are under treatment. Dietary supplements do not replace a balanced diet or medical follow-up. An IGF-1 result should be interpreted with the reference ranges of the laboratory that performed it and with your doctor. Growth hormone is a prescription drug with no recognized anti-aging indication: never take it outside medical supervision. After 65, do not reduce your protein intake without medical advice.

💬 A question about this topic?
The UltraSanté health assistant answers free of charge and right away, drawing on our articles.
Ask Léa my question →
The health letter

A weekly dose of informed health.

Every Thursday morning, a plain, useful newsletter: 1 key deep dive, 3 articles to read, 1 practical tip.

FREE Sign-up bonus: our booklet “The Circle of Lasting Habits”, sent to you by email straight away.
Unsubscribe in 1 click Data protected, never sold No spam
Get the weekly health letter